Beyond market averages, investors looking for exceptional returns turn to stock picking. Skillful choices in individual stocks have the power to substantially increase your wealth.
The closing price of Day One Biopharmaceuticals Inc (NASDAQ: DAWN) was $8.31 for the day, down -1.42% from the previous closing price of $8.43. In other words, the price has decreased by -$1.42 from its previous closing price. On the day, 3.55 million shares were traded. DAWN stock price reached its highest trading level at $8.535 during the session, while it also had its lowest trading level at $8.215.
Ratios:
Our analysis of DAWN’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 8.55 and its Current Ratio is at 8.68. In the meantime, Its Debt-to-Equity ratio is 0.01 whereas as Long-Term Debt/Eq ratio is at 0.01.
Upgrades & Downgrades
In the most recent recommendation for this company, Piper Sandler on August 19, 2025, initiated with a Overweight rating and assigned the stock a target price of $25.
On October 09, 2024, Needham reiterated its Buy rating and also lowered its target price recommendation from $32 to $33.
BofA Securities Upgraded its Underperform to Buy on August 01, 2024, whereas the target price for the stock was revised from $11 to $24.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Nov 17 ’25 when Dubow Adam sold 4,319 shares for $8.91 per share. The transaction valued at 38,503 led to the insider holds 62,626 shares of the business.
York Charles N II sold 4,062 shares of DAWN for $36,212 on Nov 17 ’25. The COO and CFO now owns 294,715 shares after completing the transaction at $8.91 per share. On Nov 17 ’25, another insider, Merendino Lauren, who serves as the Chief Commercial Officer of the company, sold 3,726 shares for $8.91 each. As a result, the insider received 33,216 and left with 50,809 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, DAWN now has a Market Capitalization of 853233472 and an Enterprise Value of 404546432. For the stock, the TTM Price-to-Sale (P/S) ratio is 6.38 while its Price-to-Book (P/B) ratio in mrq is 1.89. Its current Enterprise Value per Revenue stands at 3.026 whereas that against EBITDA is -2.491.
Stock Price History:
The Beta on a monthly basis for DAWN is -1.26, which has changed by -0.37369984 over the last 52 weeks, in comparison to a change of 0.12415576 over the same period for the S&P500. Over the past 52 weeks, DAWN has reached a high of $14.46, while it has fallen to a 52-week low of $5.64. The 50-Day Moving Average of the stock is 3.88%, while the 200-Day Moving Average is calculated to be 10.91%.
Shares Statistics:
DAWN traded an average of 1.92M shares per day over the past three months and 2088250 shares per day over the past ten days. A total of 102.68M shares are outstanding, with a floating share count of 73.55M. Insiders hold about 28.37% of the company’s shares, while institutions hold 72.19% stake in the company. Shares short for DAWN as of 1763078400 were 8969860 with a Short Ratio of 4.67, compared to 1760486400 on 10061778. Therefore, it implies a Short% of Shares Outstanding of 8969860 and a Short% of Float of 12.920000000000002.
Earnings Estimates
The firm’s stock currently is rated by 7.0 analysts. The consensus estimate for the next quarter is -$0.19, with high estimates of -$0.1 and low estimates of -$0.25.
Analysts are recommending an EPS of between -$0.62 and -$1.2 for the fiscal current year, implying an average EPS of -$0.97. EPS for the following year is -$0.65, with 8.0 analysts recommending between -$0.07 and -$1.6.
Revenue Estimates
It is expected that $90B in revenue will be generated in. The current quarter, according to 9 analysts. It ranges from a high estimate of $46.7M to a low estimate of $37.54M. As of. The current estimate, Day One Biopharmaceuticals Inc’s year-ago sales were $29.2MFor the next quarter, 9 analysts are estimating revenue of $50.86M. There is a high estimate of $54.1M for the next quarter, whereas the lowest estimate is $47.8M.
A total of 10 analysts have provided revenue estimates for DAWN’s current fiscal year. The highest revenue estimate was $151.2M, while the lowest revenue estimate was $142M, resulting in an average revenue estimate of $148.51M. In the same quarter a year ago, actual revenue was $131.16MBased on 10 analysts’ estimates, the company’s revenue will be $222.81M in the next fiscal year. The high estimate is $295M and the low estimate is $165.99M.
